Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $15.3333.

A number of equities research analysts have commented on the company. HC Wainwright restated a “buy” rating on shares of Coya Therapeutics in a research report on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Friday, July 17th. Chardan Capital restated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday, August 12th. Finally, Roth Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Coya Therapeutics in a research report on Monday, August 24th.

Coya Therapeutics Stock Up 5.9%

Shares of Coya Therapeutics stock opened at $4.64 on Tuesday. The stock has a market cap of $108.85 million, a PE ratio of -4.34 and a beta of 0.61. The business has a fifty day simple moving average of $4.66 and a 200-day simple moving average of $4.66. Coya Therapeutics has a 12 month low of $3.71 and a 12 month high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.13 million. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%. Analysts expect that Coya Therapeutics will post -1.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its stake in shares of Coya Therapeutics by 205.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 95,919 shares of the company’s stock valued at $377,000 after buying an additional 64,490 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in Coya Therapeutics in the first quarter valued at approximately $161,000. Long Corridor Asset Management Ltd bought a new stake in Coya Therapeutics in the fourth quarter worth approximately $225,000. Renaissance Technologies LLC increased its stake in shares of Coya Therapeutics by 55.4% during the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock worth $410,000 after purchasing an additional 37,064 shares during the last quarter. Finally, AXQ Capital LP bought a new position in shares of Coya Therapeutics during the 2nd quarter valued at $116,000. 39.75% of the stock is owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.